產(chǎn)品名稱：sRANKL total ELISA 產(chǎn) 地：Demeditec 產(chǎn)品貨號：DE1930042 產(chǎn)品規(guī)格：96 Tests 產(chǎn)品說明： Special remarks: This testkit measures total soluble RANKL (free and bound) in serum and plasma samples. sRANKL, receptor activator of nuclear factor (NF)-kB ligand (also: osteoprotegerin ligand, OPGL), is a part of the TNF superfamily with high similarity to other members of that protein species (SwissProt Nr. 014788). Three isoforms are produced by alternate splicing, two type II membrane proteins (ISOFORM 1, 317 AA, and ISOFORM 3, 270 AA), and a secreted molecule (ISOFORM 2, 244 AA). ISOFORM 1 is identical to previously reported RANKL and possesses intracellular, transmembrane, and extracellular domains; ISOFORM 2 does not have the intracellular and transmembrane domains, and ISOFORM 3 does not have the intracellular domain. A soluble form arises by proteolytic processing from membrane isoforms. Although all forms are bioactive, the membrane-bound proteins seem to be the homeostatic forms, while the production of soluble RANKL signals pathological conditions. RANKL, RANK, and osteoprotegerin (OPG) have been identified as the key molecular regulation system for bone remodelling. RANKL is the main stimulatory factor for the formation of mature osteoclasts and is essential for their survival. Therefore, an increase in RANKL expression leads to bone resorption and bone loss. RANKL is produced by osteoblastic lineage cells and activated T lymphocytes. It activates its specific receptor RANK, which is located on osteoclasts and dendritic cells. The effects of RANKL are counteracted by OPG, which is secreted by various tissues and acts as an endogenous soluble receptor antagonist. Imbalances of the RANKL/OPG system have been related to the pathogenesis of Paget’s disease, benign and malignant bone tumors, postmenopausal osteoporosis, rheumatoid arthritis, bone metastases and hypercalcemia. Several studies using animal models have shown that restoring the RANKL/OPG balance (e.g. by administering OPG) reduces the severity of these disorders. Indication - Postmenopausal and senile osteoporosis - Diseases with locally increased bone resorption activity - Paget´s disease - Periodontal disease - Cardiovascular disease, arterial calcification - Inflammatory diseases - Immunological disorders - Arthritis - Oncology 上海玉博生物技術(shù)有限公司在為生命科學(xué)領(lǐng)域提供豐富的產(chǎn)品與信息資源方面處于****地位，公司提供的產(chǎn)品涵蓋了二十多個(gè)國家近五十萬種產(chǎn)品，而且產(chǎn)品的數(shù)量與信息在不斷的增長和更新，公司提供的產(chǎn)品能夠使生命科學(xué)工作者加快對生物化學(xué)，分子生物學(xué)，細(xì)胞生物學(xué)以及蛋白質(zhì)組學(xué)研究的認(rèn)知，以及分子診斷和臨床醫(yī)學(xué)領(lǐng)域的應(yīng)用。
滬公網(wǎng)安備 31011002002623號
